Last reviewed · How we verify

NCT05820334

Multiple Sclerosis and Fatigue Assessment

Completed Last updated 27 January 2026
What this trial tests

trial in Multiple Sclerosis in 60 participants. Completed in 1 December 2024.

Timeline
1 April 2023
Primary endpoint
1 December 2024
1 December 2024

Quick facts

Lead sponsorAsli Demirtaş
StatusCompleted
Study typeOBSERVATIONAL
Enrollment60
Start date1 April 2023
Primary completion1 December 2024
Estimated completion1 December 2024
Sites1 location across Turkey (Türkiye)

Conditions studied

Sponsor

Asli Demirtaş

Who can join

Adults 18 to 65, any sex, with Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Fatigue in patients with Multiple Sclerosis (MS) is a problem that is seen without physical exertion and affects the majority of patients. In studies on fatigue in the literature, it has been seen that subjective methods are frequently used by using evaluation scales based on patient statements, but objective evaluation methods are not yet sufficient. This study was planned to compare the measurement results by evaluating fatigue subjectively, objectively and cognitively in MS patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05820334.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing